Peregrine Capital Management LLC Has $8.06 Million Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Peregrine Capital Management LLC grew its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 10.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 812,938 shares of the biopharmaceutical company’s stock after buying an additional 79,389 shares during the period. Peregrine Capital Management LLC owned 0.27% of Amicus Therapeutics worth $8,064,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Van ECK Associates Corp lifted its position in shares of Amicus Therapeutics by 23.1% in the fourth quarter. Van ECK Associates Corp now owns 4,657 shares of the biopharmaceutical company’s stock valued at $66,000 after buying an additional 873 shares during the last quarter. Sage Capital Advisors llc acquired a new stake in Amicus Therapeutics during the 2nd quarter worth approximately $103,000. Calton & Associates Inc. acquired a new stake in Amicus Therapeutics during the 4th quarter worth approximately $142,000. EntryPoint Capital LLC lifted its holdings in Amicus Therapeutics by 278.8% during the 1st quarter. EntryPoint Capital LLC now owns 13,218 shares of the biopharmaceutical company’s stock worth $156,000 after purchasing an additional 9,729 shares during the last quarter. Finally, Old Well Partners LLC acquired a new stake in Amicus Therapeutics during the 4th quarter worth approximately $180,000.

Analyst Ratings Changes

FOLD has been the subject of several research reports. JPMorgan Chase & Co. dropped their price target on Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a report on Friday, August 16th. Bank of America lowered their price objective on Amicus Therapeutics from $14.00 to $13.00 and set a “buy” rating on the stock in a research note on Friday, May 10th. Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a research note on Friday, August 9th. Guggenheim upgraded Amicus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective on the stock in a research note on Tuesday, May 14th. Finally, UBS Group lowered their price objective on Amicus Therapeutics from $20.00 to $19.00 and set a “buy” rating on the stock in a research note on Friday, May 10th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.14.

Amicus Therapeutics Price Performance

FOLD stock traded up $0.31 during midday trading on Friday, reaching $11.61. 2,908,965 shares of the stock were exchanged, compared to its average volume of 2,829,607. The stock has a market capitalization of $3.44 billion, a PE ratio of -23.69 and a beta of 0.71. Amicus Therapeutics, Inc. has a 52 week low of $9.02 and a 52 week high of $14.57. The company has a debt-to-equity ratio of 2.97, a current ratio of 3.03 and a quick ratio of 2.61. The company has a fifty day moving average price of $10.64 and a 200 day moving average price of $10.95.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.05). The business had revenue of $126.67 million for the quarter, compared to analyst estimates of $121.21 million. Amicus Therapeutics had a negative return on equity of 77.08% and a negative net margin of 34.73%. Amicus Therapeutics’s quarterly revenue was up 34.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.15) EPS. As a group, analysts expect that Amicus Therapeutics, Inc. will post -0.12 EPS for the current fiscal year.

Insider Buying and Selling

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 6,100 shares of Amicus Therapeutics stock in a transaction dated Friday, July 5th. The stock was sold at an average price of $10.00, for a total transaction of $61,000.00. Following the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at approximately $8,866,540. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $10.34, for a total transaction of $77,550.00. Following the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at approximately $9,168,002.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Bradley L. Campbell sold 6,100 shares of Amicus Therapeutics stock in a transaction dated Friday, July 5th. The stock was sold at an average price of $10.00, for a total value of $61,000.00. Following the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at $8,866,540. The disclosure for this sale can be found here. 2.20% of the stock is currently owned by corporate insiders.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.